56 completed, 2 withdrawn, 1 not yet recruiting, 1 recruiting. 21 Phase 3, 17 Phase 2, 10 Phase 4, 8 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 20, Withdrawn 1 |
| Phase 2 | 17 | Completed 15, Not yet recruiting 1, Withdrawn 1 |
| Phase 4 | 10 | Completed 10 |
| Phase 1 | 8 | Completed 8 |
| Not applicable | 1 | Unknown 1 |
Follow Seqirus: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 56 | 2026-12-01 | 2026-09-17 |
| Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults ARCT-2303, Influenza vaccine, Influenza vaccine, adjuvanted - COVID-19 | Phase 3 | Completed | Arcturus Therapeutics, Inc. | 1514 | 2024-03-27 | 2025-12-12 |
| Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults - Influenza, Human | Phase 1 | Completed | Arcturus Therapeutics, Inc. | 139 | 2024-01-22 | 2025-10-03 |
| The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older Investigational aQIVc, licensed QIVr, licensed aQIV - Influenza, Human | Phase 3 | Completed | Seqirus | 7741 | 2023-11-03 | 2025-04-27 |
| A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age aQIV or aTIV, QIV or TIV - Influenza, Human | Phase 3 | Completed | Seqirus | 38769 | 2023-10-23 | 2026-09-02 |
| Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3 - Influenza, Human | Phase 1 | Completed | Seqirus | 96 | 2023-10-05 | 2024-11-27 |
| Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4) - Influenza, Community-acquired Pneumonia | Recruiting | Kaiser Permanente | 1500000 | 2023-08-17 | 2026-08-05 | |
| Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59 - Influenza, Human, Infections | Phase 1 | Completed | Seqirus | 600 | 2023-06-15 | 2026-09-21 |
| Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22 - Influenza, Human, Infections | Phase 2 | Completed | Seqirus | 480 | 2023-06-07 | 2024-12-13 |
| Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1 - Influenza, Human | Phase 2 | Completed | Seqirus | 1056 | 2022-08-25 | 2026-06-30 |
| A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed aH5N6c on Day 1, aH5N6c on Day 22, Placebo on Day 22 - Influenza, Human, Influenza in Birds | Phase 2 | Completed | Seqirus | 260 | 2022-07-18 | 2026-05-13 |
| Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray Observational - Allergic Rhinitis | Completed | Community and Patient Preference Research Pty Ltd | 426 | 2021-11-08 | 2024-04-12 | |
| A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age aQIV, Comparator QIV - Influenza, Human | Phase 3 | Completed | Seqirus | 2044 | 2021-09-30 | 2023-09-28 |
| Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults aQII-1, aQII-3 Investigational, aQII-6 Investigational - Influenza | Phase 2 | Completed | Seqirus | 839 | 2021-04-13 | 2024-10-10 |
| A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine H5N1 antigen combined with MF59 adjuvant - Influenza, Human | Phase 2 | Completed | Seqirus | 420 | 2020-12-19 | 2024-03-13 |
| An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator - Influenza | Phase 2 / Phase 3 | Withdrawn | Seqirus | 2020-12-15 | 2021-03-23 | |
| Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults Investigational aIIV4c, IIV4c, aIIV4 - Influenza, Human | Phase 2 | Completed | Seqirus | 471 | 2020-10-08 | 2024-04-17 |
| Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects QIVc, Comparator QIV - Influenza, Human | Phase 3 | Completed | Seqirus | 2414 | 2019-09-06 | 2022-01-12 |
| Efficacy Study With QIVc in Pediatric Subjects QIVc, Comparator - Influenza, Human | Phase 3 | Completed | Seqirus | 5723 | 2019-05-13 | 2025-03-04 |
| Adjuvanted Influenza Vaccination Year 2 Follow-On Survey Influenza - Influenza, Influenza-like Illness | Completed | Insight Therapeutics, LLC | 598 | 2018-07-13 | 2023-03-16 |
Showing 20 of 61. Sign in to see all of them.
Influenza, Human (56) · Virus Diseases (6) · Influenza in Birds (4) · Infections (3) · Respiratory Tract Infections (3) · Congenital Abnormalities (2) · COVID-19 (1) · Community-Acquired Pneumonia (1) · Orthomyxoviridae Infections (1) · Patient Preference (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Rhinitis, Allergic (1)
Influenza Vaccines (16) · Afluria (3) · fluad vaccine (2) · Adjuvants, Pharmaceutic (1) · Aging (1) · Antigens (1) · Antigens, Surface (1) · BNT162 Vaccine (1) · Blood Specimen Collection (1) · Boostrix (1) · Cell Culture Techniques (1) · Fluzone High-Dose (1) · MF59 oil emulsion (1) · Watchful Waiting (1)
United States (31) · Australia (17) · Philippines (12) · United Kingdom (7) · Estonia (6) · Finland (6) · Germany (6) · Thailand (6) · Poland (5) · New Zealand (4) · Bulgaria (3) · Czechia (3) · Italy (3) · Lithuania (3) · Romania (3)
H. Edward Davidson, PharmD, MPH (2) · Peter Richmond, Dr (2) · Stefan Gravenstein, MD, MPH (2) · Terry M Nolan, Prof (2) · Vincent Mor, PhD (2)
PMID 18599164, PMID 41855648, PMID 18801398, PMID 19745216, PMID 20026597, PMID 20874515, PMID 22426371, PMID 23551933, PMID 24732325, PMID 25454878, PMID 27595443, PMID 28302411, PMID 28390934, PMID 29631857, PMID 30057283, PMID 31635976, PMID 32404782, PMID 32882710, PMID 33400778, PMID 33577767, PMID 34644472, PMID 35455245, PMID 36214072, PMID 36951196, PMID 39946829, PMID 40896462, PMID 41962984, PMID 42081247, PMID 42721997
2015 (3), 2016 (2), 2008 (1), 2009 (1), 2014 (1), 2018 (1)